Chimie physique générale, Chimie thérapeutique Bertrand RIHN .................................. Biochimie ,
Chimie thérapeutique Chimie thérapeutique ,
Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique ,
Chimie organique Biophysique ,
Pharmacie galénique 2) Clinique de la, Biochimie et Biologie Rhinoconjonctivite allergique, p.14 ,
14 2.1.1.1), p.14 ,
18 2.2.1), 18 2.2.2) Les conjonctivites allergiques saisonnières et perannuelles ,
) Comment mesurer l'altération de la qualité de vie ?, p.28 ,
36 4.3.1) principe de production, p.38 ,
) Efficacité sur l'inflammation allergique, p.68 ,
Pathogenesis of allergic rhinitis????????????, Journal of Allergy and Clinical Immunology, vol.99, issue.2, pp.763-772, 1997. ,
DOI : 10.1016/S0091-6749(97)70125-8
Immunologic influences on allergy and the TH1/TH2 balance, Journal of Allergy and Clinical Immunology, vol.113, issue.3, pp.395-400, 2004. ,
DOI : 10.1016/j.jaci.2003.11.025
Molecular and cellular mechanisms of allergic disease?????????, Journal of Allergy and Clinical Immunology, vol.108, issue.2, pp.65-71, 2001. ,
DOI : 10.1067/mai.2001.116436
Immunoglobulin E: Role in asthma and allergic disease: Lessons from the clinic, Pharmacology & Therapeutics, vol.113, issue.1, pp.121-154, 2007. ,
DOI : 10.1016/j.pharmthera.2006.07.003
7. Rhinitis and sinusitis, Journal of Allergy and Clinical Immunology, vol.111, issue.2, pp.520-529, 2003. ,
DOI : 10.1067/mai.2003.82
Allergic Rhinitis and Its Impact on Asthma, Journal of Allergy and Clinical Immunology, vol.108, issue.5, pp.147-334, 2001. ,
DOI : 10.1067/mai.2001.118891
URL : https://hal.archives-ouvertes.fr/inserm-00815533
Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment, Journal of Allergy and Clinical Immunology, vol.115, issue.1, pp.118-140, 2005. ,
DOI : 10.1016/j.jaci.2004.10.042
One Airway, One Disease, Chest, vol.111, issue.2, pp.11-16, 1997. ,
DOI : 10.1378/chest.111.2_Supplement.11S
The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee, Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC Lancet, pp.1225-1257, 1998. ,
Severity and impairment of allergic rhinitis in patients consulting in primary care, Journal of Allergy and Clinical Immunology, vol.117, issue.1, pp.158-62, 2006. ,
DOI : 10.1016/j.jaci.2005.09.047
The correlation between allergic rhinitis and sleep disturbance, Journal of Allergy and Clinical Immunology, vol.114, pp.139-145, 2004. ,
DOI : 10.1016/j.jaci.2004.08.044
A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis, Journal of Allergy and Clinical Immunology, vol.111, issue.3, pp.484-490, 2003. ,
DOI : 10.1067/mai.2003.137
A cost of illness study of allergic rhinitis in the United States, Journal of Allergy and Clinical Immunology, vol.99, issue.1, pp.22-27, 1997. ,
DOI : 10.1016/S0091-6749(97)70296-3
Anticorps monoclonaux et thérapeutiques Pathologie biologie, pp.351-64, 2004. ,
DOI : 10.1016/j.patbio.2003.09.017
Les anticorps monoclonaux à usage thérapeutique : de la conception aux indications ,
L'omalizumab : un nouvel anti IgE pour le traitement de l'asthme sévère, Forum Med Suisse, vol.8, pp.191-195, 2008. ,
Anti-IgE therapy with omalizumab in asthma and allergic rhinitis Acta pharmaceutica, pp.123-138, 2005. ,
The binding site on human immunoglobulin E for its high affinity receptor, J Biol Chem, vol.269, pp.26368-26373, 1994. ,
A monoclonal anti-IgE antibody MedGenMed, p.27, 2005. ,
Humanization of an antibody directed against IgE, J immunol, vol.151, pp.2623-2632, 1993. ,
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab, British Journal of Clinical Pharmacology, vol.15, issue.5, pp.548-561, 2007. ,
DOI : 10.1007/BF00173275
Anti-IgE for the Treatment of Allergic Rhinitis – and Eventually Nasal Polyps?, International Archives of Allergy and Immunology, vol.148, issue.2, pp.87-98, 2009. ,
DOI : 10.1159/000155739
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis??????????????????, Journal of Allergy and Clinical Immunology, vol.100, issue.1, pp.110-121, 1997. ,
DOI : 10.1016/S0091-6749(97)70202-1
Characterization of Complex Formation by Humanized Anti-IgE Monoclonal Antibody and Monoclonal Human IgE, Biochemistry, vol.34, issue.33, pp.635-642, 1995. ,
DOI : 10.1021/bi00033a020
Omalizumab rapidly decreases nasal allergic response and Fc??RI on basophils???, Journal of Allergy and Clinical Immunology, vol.113, issue.2, pp.297-302, 2004. ,
DOI : 10.1016/j.jaci.2003.11.044
Omalizumab-induced reductions in mast cell Fc??RI expression and function, Journal of Allergy and Clinical Immunology, vol.114, issue.3, pp.527-530, 2004. ,
DOI : 10.1016/j.jaci.2004.06.032
Anti-IgE as a mast cell???stabilizing therapeutic agent, Journal of Allergy and Clinical Immunology, vol.117, issue.6, pp.1203-1212, 2006. ,
DOI : 10.1016/j.jaci.2006.04.005
Omalizumab treatment downregulates dendritic cell Fc??RI expression, Journal of Allergy and Clinical Immunology, vol.112, issue.6, pp.1147-1154, 2003. ,
DOI : 10.1016/j.jaci.2003.10.003
A conformational rearrangement upon binding og IgE to its high affinity receptor, J Biol Chem, vol.271, pp.19256-19263, 1996. ,
Omalizumab dosing via the recommended card versus use of the published formula, Journal of Allergy and Clinical Immunology, vol.117, issue.3, pp.708-709, 2006. ,
DOI : 10.1016/j.jaci.2005.11.042
Omalizumab: where does it fit into current asthma management?, Cleveland Clinic Journal of Medicine, vol.71, issue.3, pp.251-261, 2004. ,
DOI : 10.3949/ccjm.71.3.251
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen???induced seasonal allergic rhinitis, Journal of Allergy and Clinical Immunology, vol.106, issue.2, pp.253-259, 2000. ,
DOI : 10.1067/mai.2000.108310
Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis, a randomized controlled trial JAMA, pp.2956-2967, 2001. ,
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis, Annals of Allergy, Asthma & Immunology, vol.91, issue.2, pp.160-167, 2003. ,
DOI : 10.1016/S1081-1206(10)62171-0
Omalizumab inhibits allergen challenge-induced nasal response, European Respiratory Journal, vol.23, issue.3, pp.414-418, 2004. ,
DOI : 10.1183/09031936.04.00024504
URL : http://erj.ersjournals.com/content/erj/23/3/414.full.pdf
The effect of omalizumab on nasal allergic inflammation, Journal of Allergy and Clinical Immunology, vol.110, issue.1, pp.68-71, 2002. ,
DOI : 10.1067/mai.2002.125488
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis, Journal of Allergy and Clinical Immunology, vol.117, issue.1, pp.134-140, 2006. ,
DOI : 10.1016/j.jaci.2005.09.036
Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy, Journal of Allergy and Clinical Immunology, vol.121, issue.2, pp.506-511, 2008. ,
DOI : 10.1016/j.jaci.2007.11.026
Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis, Allergy, vol.63, issue.1, pp.81-84, 2009. ,
DOI : 10.1164/ajrccm/147.4.832
Safety and Tolerability of Omalizumab (Xolair<SUP>??</SUP>), a Recombinant Humanized Monoclonal Anti-IgE Antibody, Clinical Reviews in Allergy & Immunology, vol.29, issue.1, pp.31-48, 2005. ,
DOI : 10.1385/CRIAI:29:1:031
Safety and tolerability of omalizumab, Clinical & Experimental Allergy, vol.39, issue.6, pp.788-97, 2009. ,
DOI : 10.1111/j.1365-2222.2009.03214.x
Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Allergy, pp.149-53, 2007. ,
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model, Journal of Allergy and Clinical Immunology, vol.120, issue.5, pp.1146-52, 2007. ,
DOI : 10.1016/j.jaci.2007.07.055
Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma, Journal of Allergy and Clinical Immunology, vol.114, issue.2, pp.265-269, 2004. ,
DOI : 10.1016/j.jaci.2004.05.049